HUP0203863A2 - Az axon növekedés Nogo-receptor közvetítette blokkolása - Google Patents

Az axon növekedés Nogo-receptor közvetítette blokkolása

Info

Publication number
HUP0203863A2
HUP0203863A2 HU0203863A HUP0203863A HUP0203863A2 HU P0203863 A2 HUP0203863 A2 HU P0203863A2 HU 0203863 A HU0203863 A HU 0203863A HU P0203863 A HUP0203863 A HU P0203863A HU P0203863 A2 HUP0203863 A2 HU P0203863A2
Authority
HU
Hungary
Prior art keywords
nogo
receptor
axon growth
blocking
nogo receptor
Prior art date
Application number
HU0203863A
Other languages
English (en)
Inventor
Stephen M. Strittmatter
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of HUP0203863A2 publication Critical patent/HUP0203863A2/hu
Publication of HUP0203863A3 publication Critical patent/HUP0203863A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

A találmány tárgyát humán és egér eredetű gének képezik, amelyek aNogo-fehérje receptorát kódolják, amely receptor képes azaxonnövekedés szabályozására. A Nogo-receptorgének szelektív módonexpresszálódnak a neuronok axonjaiban és dendritjeiben a központiidegrendszerben az axonnövekedés során. A találmány tárgyát képeziktovábbá készítmények és eljárások az axonnövekedés Nogo-receptorközvetítette gátlásának szelektív blokkolására a Nogo-fehérje és aNogo-receptor kölcsönhatásának blokkolása útján. A Nogo-kölcsönhatásának blokkolása a receptorával a Nogo gátló hatásainak ablokkolását jelenti az axonnövekedésben, ami ennek következtébenfokozódást eredményez az axonnövekedésben. A találmány szerintimegoldás elsősorban a központi idegrendszer bizonyosrendellenességeinek kezelésére, illetve megelőzésére alkalmazható. Ó
HU0203863A 2000-01-12 2001-01-12 Nogo receptor-mediated blockade of axonal growth HUP0203863A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17570700P 2000-01-12 2000-01-12
US20736600P 2000-05-26 2000-05-26
US23637800P 2000-09-29 2000-09-29
PCT/US2001/001041 WO2001051520A2 (en) 2000-01-12 2001-01-12 Nogo receptor-mediated blockade of axonal growth

Publications (2)

Publication Number Publication Date
HUP0203863A2 true HUP0203863A2 (hu) 2003-03-28
HUP0203863A3 HUP0203863A3 (en) 2008-03-28

Family

ID=27390581

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203863A HUP0203863A3 (en) 2000-01-12 2001-01-12 Nogo receptor-mediated blockade of axonal growth

Country Status (27)

Country Link
US (1) US20020012965A1 (hu)
EP (2) EP1248803B1 (hu)
JP (1) JP4763207B2 (hu)
KR (1) KR100828058B1 (hu)
CN (1) CN100354307C (hu)
AT (1) ATE466882T1 (hu)
AU (1) AU784349C (hu)
BG (1) BG106907A (hu)
BR (1) BR0107613A (hu)
CA (1) CA2397199C (hu)
CZ (1) CZ20022438A3 (hu)
DE (1) DE60142023D1 (hu)
EA (1) EA008480B1 (hu)
EE (1) EE200200386A (hu)
ES (1) ES2341842T3 (hu)
GE (1) GEP20063830B (hu)
HK (1) HK1051543A1 (hu)
HU (1) HUP0203863A3 (hu)
IL (2) IL150566A0 (hu)
IS (1) IS6455A (hu)
MX (1) MXPA02006885A (hu)
NO (1) NO20023387L (hu)
NZ (2) NZ541694A (hu)
PL (1) PL356887A1 (hu)
SK (1) SK9992002A3 (hu)
WO (1) WO2001051520A2 (hu)
YU (1) YU53502A (hu)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US7723488B2 (en) 1998-03-27 2010-05-25 Genentech, Inc. Monoclonal antibodies to secreted and transmembrane polypeptides
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE466882T1 (de) * 2000-01-12 2010-05-15 Univ Yale Nogo rezeptor-vermittelte blockade des axonalen wachstums
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
EP1325130B1 (en) 2000-10-06 2010-02-24 Yale University Nogo receptor homologs
GB0101312D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
EP1423427A2 (en) * 2001-08-27 2004-06-02 Novartis AG Nogo receptor homologues and their use
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
FR2841261B1 (fr) * 2002-06-25 2004-08-27 Univ Pasteur Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire
EA200500330A1 (ru) * 2002-08-10 2006-06-30 Йейл Юниверсити Антагонисты nogo рецепторов
EP1534736B1 (en) * 2002-08-10 2010-06-02 Yale University Nogo receptor antagonists
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
ATE466870T1 (de) * 2002-12-06 2010-05-15 Zhi Cheng Xiao Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
PT2248899E (pt) 2003-03-19 2015-09-23 Biogen Ma Inc Proteína de ligação do receptor nogo
WO2004090103A2 (en) * 2003-04-04 2004-10-21 University Of Rochester Identification of novel nogo-receptors and methods related thereto
CA2522649A1 (en) * 2003-04-16 2004-11-04 Biogen Idec Ma Inc. Treatment of conditions involving amyloid plaques
WO2004110353A2 (en) * 2003-05-15 2004-12-23 The Board Of Trustees Of The Leland Stanford Junior University Novel immunomodulating peptide
MX348062B (es) * 2003-05-16 2017-05-26 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
WO2005059515A2 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
CA2582581A1 (en) * 2004-10-01 2006-05-04 Yale University Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof
US20090137484A1 (en) * 2004-12-01 2009-05-28 National University Of Singapore Neuronal Network-Interacting Peptide
US7893032B2 (en) * 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
EP2238986A3 (en) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
US7485295B2 (en) 2005-09-26 2009-02-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
BRPI0707276B1 (pt) 2006-01-27 2021-08-31 Biogen Ma Inc Polipeptídeo de fusão antagonista de receptor nogo
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのＮｏｇｏ受容体−１（ＮｇＲ１）アンタゴニストの使用
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
CA2670368C (en) 2006-11-21 2018-05-29 Abbott Laboratories Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXONE GROWTH AND CHRONIC MEDALLIONAL LESIONAL HEALING
US20090285803A1 (en) * 2008-05-13 2009-11-19 Jasvinder Atwal ANTI-PirB ANTIBODIES
WO2010005570A2 (en) 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprising antibodies to lingo or fragments thereof
EA030716B1 (ru) 2012-05-14 2018-09-28 Байоджен Ма Инк. Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
CN104935294B (zh) * 2014-03-20 2018-07-20 晶宏半导体股份有限公司 振荡器
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
CN109354605B (zh) * 2015-07-17 2021-02-05 暨南大学 一种Nogo-A受体结合肽及其衍生物与应用
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5466585A (en) 1986-04-15 1995-11-14 Ciba-Geigy Corporation Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
AU3069189A (en) 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same
EP0432216A1 (en) 1988-09-01 1991-06-19 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
ATE124726T1 (de) 1988-11-04 1995-07-15 Zuerich Erziehungsdirektion Wachstumsregelfaktoren für neuriten.
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
CA2119443C (en) 1991-09-20 1999-11-02 James M. Roberts Human cyclin e
PT620849E (pt) 1992-01-07 2003-11-28 Elan Pharm Inc Modelos animais transgenicos para a doenca de alzheimer
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
CA2117889A1 (en) 1993-02-11 1994-08-18 Martin E. Schwab A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DK75393D0 (da) 1993-06-24 1993-06-24 Symbicom Ab Production of protein
AU700315B2 (en) 1993-10-28 1998-12-24 Houston Advanced Research Center Microfabricated, flowthrough porous apparatus for discrete detection of binding reactions
WO1995024488A1 (en) 1994-03-09 1995-09-14 Abbott Laboratories Transgenic animals producing oligosaccharides and glycoconjugates
FR2718329B1 (fr) 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
US5908969A (en) 1994-05-13 1999-06-01 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
WO1999066041A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
CA2311640A1 (en) * 1997-12-03 1999-06-10 Genentech, Inc. Polypeptides and nucleic acids encoding the same
AU762055B2 (en) * 1998-03-10 2003-06-19 Genentech Inc. Novel polypeptides and nucleic acids encoding the same
DK1490386T3 (da) * 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
WO1999053945A1 (en) 1998-04-16 1999-10-28 Samuel David Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
AU741133B2 (en) * 1998-04-23 2001-11-22 Genentech Inc. SH2 domain-containing peptides
CA2326001A1 (en) * 1998-04-24 1999-11-04 Genentech, Inc. Fizz proteins
AU761340B2 (en) * 1998-06-02 2003-06-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CZ304224B6 (cs) * 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
AU771751C (en) * 1998-12-01 2006-04-06 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
JP3993746B2 (ja) * 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
JP2004516227A (ja) * 1999-03-08 2004-06-03 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物と方法
EP1263948A2 (en) * 1999-03-08 2002-12-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
AU3632600A (en) * 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
WO2001009162A2 (en) * 1999-07-30 2001-02-08 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
ATE466882T1 (de) * 2000-01-12 2010-05-15 Univ Yale Nogo rezeptor-vermittelte blockade des axonalen wachstums

Also Published As

Publication number Publication date
AU2940101A (en) 2001-07-24
AU784349C (en) 2006-09-28
NZ520065A (en) 2006-02-24
NO20023387D0 (no) 2002-07-12
HUP0203863A3 (en) 2008-03-28
GEP20063830B (en) 2006-05-25
IS6455A (is) 2002-07-03
WO2001051520A2 (en) 2001-07-19
US20020012965A1 (en) 2002-01-31
JP2003519481A (ja) 2003-06-24
CA2397199A1 (en) 2001-07-19
DE60142023D1 (de) 2010-06-17
WO2001051520A9 (en) 2002-07-18
PL356887A1 (en) 2004-07-12
AU784349B2 (en) 2006-03-16
ATE466882T1 (de) 2010-05-15
WO2001051520A3 (en) 2002-04-18
NO20023387L (no) 2002-09-11
KR20020097157A (ko) 2002-12-31
EA008480B1 (ru) 2007-06-29
HK1051543A1 (zh) 2003-08-08
EP1248803B1 (en) 2010-05-05
SK9992002A3 (en) 2003-05-02
YU53502A (sh) 2005-11-28
IL150566A (en) 2008-03-20
CN1404488A (zh) 2003-03-19
EA200200755A1 (ru) 2002-12-26
BR0107613A (pt) 2002-11-19
NZ541694A (en) 2006-08-31
ES2341842T3 (es) 2010-06-29
MXPA02006885A (es) 2004-04-05
CA2397199C (en) 2013-12-24
CZ20022438A3 (cs) 2002-10-16
EP1248803A2 (en) 2002-10-16
EP2163561A1 (en) 2010-03-17
JP4763207B2 (ja) 2011-08-31
BG106907A (bg) 2003-05-30
KR100828058B1 (ko) 2008-05-09
IL150566A0 (en) 2003-02-12
EE200200386A (et) 2003-12-15
CN100354307C (zh) 2007-12-12

Similar Documents

Publication Publication Date Title
HUP0203863A2 (hu) Az axon növekedés Nogo-receptor közvetítette blokkolása
Andersson Potential benefits of muscarinic M3 receptor selectivity
Yun et al. Effect of electroacupuncture on the stress-induced changes in brain-derived neurotrophic factor expression in rat hippocampus
Sessle Mechanisms of oral somatosensory and motor functions and their clinical correlates
Corbett et al. Lost in translation: rethinking approaches to stroke recovery
Tang Molecular genetic determinants of human brain size
Levkovitz et al. Transcranial magnetic stimulation and antidepressive drugs share similar cellular effects in rat hippocampus
WO2004006846A3 (en) Receptor-type kinase modulators and methods of use
WO2004084835A3 (en) Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
EP0788307A4 (en) MODULATION BY OLIGONUCLEOTIDES OF THE PROTEIN ASSOCIATED WITH MULTIPLE ANTI-CANCER RESISTANCE
WO2009033027A3 (en) Suppression of scn9a gene expression and/or function for the treatment of pain
Boehme et al. Impact of indomethacin on neuroinflammation and hippocampal neurogenesis in aged mice
Di Bonito et al. Hox genes and region‐specific sensorimotor circuit formation in the hindbrain and spinal cord
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
HK1081880A1 (en) Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
WO2004026107A3 (en) Kits and methods for assessing skin health
MX2023012216A (es) Composiciones y metodos para modular la expresion de pnpla3.
Łukasiuk et al. AP-1 and CRE DNA binding activities in rat brain following pentylenetetrazole induced seizures
DE60137414D1 (de) Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
WO2002083182A3 (en) The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
WO2002024889A3 (en) Optimized cardiac contraction through differential phosphorylation of myosin
WO2022266527A8 (en) Methods of generating sacral neural crest lineages and uses thereof
Shirokawa et al. Age-related changes in the release and uptake activity of presynaptic axon terminals of rat locus coeruleus neurons
Tchélingérian et al. Widespread neuronal expression of c-Fos throughout the brain and local expression in glia following a hippocampal injury

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished